Duopharma concludes supply deal for 6.4m doses of Sputnik V vaccine


Duopharma Biotech said the supply of the 6.4 million doses of the Sputnik V vaccine is subject to the approval by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.

KUALA LUMPUR: Duopharma Biotech Bhd has concluded the supply agreements with the Malaysian Government and Russian Direct Investment Fund (RDIF) for the supply of 6.4 million doses of the Sputnik V vaccine.

In a statement on Tuesday, it said the supply of the vaccine is subject to the approval of the vaccine by the Drug Control Authority of Malaysia, as well as other terms and conditions of supply.

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Japan exports set record in October on strong chip-related demand
Nvidia chair says the board will not rehire Huang as CEO
Trading ideas: Steel Hawk, Kerjaya, HeiTech, Sum, Vantris, Citaglobal, TM, Feytech, Skyechip, SP Setia, Alpha IVF, Zetrix, Duopharma, Ranhill, Dialog, 99 Speed Mart, Solarvest, Hap Seng, MR DIY
Telus rejects Quebecor’s US$22.5bil bid
Solarvest maintains positive outlook for RE in FY27
Singapore exports surge 80% as non-electronics lead
Fed’s Hammack prefers gradual, steady rate hikes
US to curb China’s remote access to Nvidia chips
Asean topples East Asia in investment race
HeiTech Padu wins RM5.18mil deal extension

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read